| Autor: |
Widjaja AA; Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore. Electronic address: anissa.widjaja@duke-nus.edu.sg., Cook SA; Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore; National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore; MRC-London Institute of Medical Sciences, Hammersmith Hospital Campus, London, United Kingdom. Electronic address: stuart.cook@duke-nus.edu.sg. |
| Jazyk: |
angličtina |
| Zdroj: |
The American journal of pathology [Am J Pathol] 2023 Dec; Vol. 193 (12), pp. 1910-1913. Date of Electronic Publication: 2023 Oct 09. |
| DOI: |
10.1016/j.ajpath.2023.09.011 |
| Abstrakt: |
Competing Interests: Disclosure Statement A.A.W. and S.A.C. are co-inventors of the patents US11339216B2 and WO2021255182A1, which have been licensed to Boehringer Ingelheim and VVB Bio, respectively. S.A.C. is inventor on the patents WO/2018/109174 and WO/2018/109170. S.A.C. is a co-founder and shareholder of Enleofen Bio Pte Ltd and VVB Bio Pte Ltd. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
